BFNH Arquivamentos da SEC - BioForce Nanosciences Holdings, Inc.- Relatório Anual, Declaração de Procuração, Prospecto

Estatísticas Básicas

CIK

1310488

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioForce Nanosciences Holdings, Inc.

SEC Filings (Chronological Order)

Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.

May 19, 2026	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) O U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in
May 13, 2026	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 15, 2026	EX-10.1	Chairman of the Board / Chief Executive Officer / President Exhibit 10.1 Chairman of the Board / Chief Executive Officer / President Compensation AGREEMENT This Chairman, Chief Executive Officer (CEO) and President Compensation Agreement (this “Agreement”) is made as of the 31st day of March, 2020 by and among Bioforce Nanosciences Holdings, Inc. (BFNH) a Nevada Corporation, having its principal place of business at 2020 General Booth Blvd., Unit 230 Virgi
April 15, 2026	10-K	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada
April 15, 2026	EX-10.2	Director/ Chief Financial Officer/ Secretary Exhibit 10.2 Director/ Chief Financial Officer/ Secretary Compensation AGREEMENT This Director, Chief Financial Officer/ Secretary (DCFOS) Compensation Agreement (this “Agreement”) is made as of the 31st day of March 2020 by and among Bioforce Nanosciences Holdings, Inc. (BFNH) a Delaware Corporation, having its principal place of business at 2020 General Booth Blvd., Unit 230 Virginia Beach, VA 2
March 31, 2026	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 19, 2025	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15( U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie
November 13, 2025	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 11, 2025	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in
May 13, 2025	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) O U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in
April 8, 2025	10-K	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SEC U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada
March 28, 2025	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [ X ] Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 8, 2024	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15( U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie
August 7, 2024	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in
May 7, 2024	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission
May 3, 2024	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) O U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in
April 1, 2024	10-K	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SEC U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada
November 3, 2023	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15( U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie
August 1, 2023	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in
May 9, 2023	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) O U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in
March 28, 2023	10-K	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (S
November 2, 2022	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as spec
July 27, 2022	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified
May 5, 2022	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No.1 to Form 10-Q) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 [ ] TRANSITIO U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No.1 to Form 10-Q) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exac
May 5, 2022	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15( U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie
February 11, 2022	10-K	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074
November 30, 2021	EX-17.1	Merle Ferguson 2020 General Booth Blvd., Suite 230 Virginia Beach, Virginia 23454 EX-17.1 2 ex171.htm RESIGNATION LETTER Merle Ferguson 2020 General Booth Blvd., Suite 230 Virginia Beach, Virginia 23454 November 29, 2021 Board of Directors BioForce Nanoscience, Inc. 2020 General Booth Blvd., Suite 253 Virginia Beach, Virginia 23454 Dear Board of Directors, I, Merle Ferguson, on the close of business, Monday, November 29, 2021, hereby resign as BioForce Nanosciences Holdings, In
November 30, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2021 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation
October 28, 2021	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 1 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as spec
July 30, 2021	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1 to Form 10-Q) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. ☐ TRANSITION U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1 to Form 10-Q) ? ?QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. ? ?TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 ? BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exa
July 30, 2021	EX-10.1	CONSULTING AGREEMENT Exhibit 10.1 CONSULTING AGREEMENT BioForce NanoSciences Holdings, Inc. desires to have services provided by Aldo Dalla-Vecchia. Therefore, the parties agree as follows: 1. DESCRIPTION OF SERVICES. Beginning on April 16, 2021, Aldo Dalla-Vecchia will provide the following services (collectively, the "Services"): General Consulting for Management 2. PERFORMANCE OF SERVICES. The manner in which the S
July 29, 2021	EX-10.1	CONSULTING AGREEMENT Exhibit 10.1 CONSULTING AGREEMENT BioForce NanoSciences Holdings, Inc. desires to have services provided by Aldo Dalla-Vecchia. Therefore, the parties agree as follows: 1. DESCRIPTION OF SERVICES. Beginning on April 16, 2021, Aldo Dalla-Vecchia will provide the following services (collectively, the "Services"): General Consulting for Management 2. PERFORMANCE OF SERVICES. The manner in which the S
July 29, 2021	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. [ ] TRANSITION REPORT UNDER SECTION 13 OR 1 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] ?QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. [ ] ?TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 ? BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as spec
June 2, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 02, 2021 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Co
April 27, 2021	10-Q	Quarterly Report - QTR. REPORT -MARCH 31, 2021 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifi
February 16, 2021	10-K	Annual Report - YEAR END REPORT DEC. 31, 2020 10-K 1 bfnh01222021form10kdec2020.htm YEAR END REPORT DEC. 31, 2020 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS
December 4, 2020	8-K	- CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 4, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 85-2138858 (State or other jurisdiction of incorporation)
October 23, 2020	10-Q	Quarterly Report - QTR. REPORT - SEPT. 30, 2020 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as spe
October 13, 2020	8-K	- CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 09, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation)
July 22, 2020	EX-10.7	RSDL ENTERPRISES CONSULTING AGREEMENT Exhibit 10.7 RSDL ENTERPRISES CONSULTING AGREEMENT BioForce NanoSciences Holdings, Inc. desires to have services provided by Aldo Dalla-Vecchia of RSDL Enterprises. Therefore, the parties agree as follows: 1. DESCRIPTION OF SERVICES. Beginning on May 25, 2020, Aldo Dalla-Vecchia will provide the following services (collectively, the "Services"): General Consulting for Management 2. PERFORMANCE OF
July 22, 2020	EX-10.8	MEMORANDUM OF UNDERSTANDING Converted by EDGARwiz Exhibit 10.8 MEMORANDUM OF UNDERSTANDING This Memorandum of Understanding (“MOU”), dated July 14, 2020 is by and between BioForce Nanosciences Holdings, Inc. (“BFNH”), a Nevada Corporation and Element Global, Inc., a Utah Corporation (ELGL) (BFNH and ELGL may individually referred to hereinafter as “Party” collectively referred to hereinafter as the “Parties”). This MOU sets
July 22, 2020	10-Q	Quarterly Report - QTR. REPORT - JUNE 30, 2020 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020. [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie
July 14, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 14, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Co
July 9, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Com
July 9, 2020	8-K/A	Other Events 8-K/A 1 bfnh07092020form8ka.htm AMENDED: CHANGED WORD "FORMERLY" WITH "FORMALLY" UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No.1 to Form 8-K) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registr
May 18, 2020	8-K	Current Report 8-K 1 bfnh05182020form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State
May 4, 2020	EX-10.4	SUBSCRIPTION AGREEMENT Exhibit #10.4 SUBSCRIPTION AGREEMENT TO: The Board of Directors BioForce Nanosciences Holdings, Inc. 2020 General Booth Blvd., Unit 230 Virginia Beach, VA 23454 Dear Director: The undersigned, Merle Ferguson, hereby subscribes to 1,500,000 shares of the $0.0001 par value Preferred Series ‘A’ stock (the "Shares") of BioForce Nanosciences Holdings, Inc. (BFNH) a corporation duly organized under the
May 4, 2020	10-Q	Quarterly Report - QTR. REPORT -MARCH 31, 2020 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie
May 4, 2020	EX-10.1	Employment Agreement – Merle Ferguson (1) Exhibit 10.1 Chairman of the Board/ President/CEO Compensation AGREEMENT This Chairman and President Compensation Agreement (this “Agreement”) is made as of the 31st day of March, 2020 by and among Bioforce Nanosciences Holdings, Inc. (BFNH) a Nevada Corporation, having its principal place of business at 2020 General Booth Blvd., Unit 230 Virginia Beach, VA 23454 (“Company”), and Merle Ferguson, C
May 4, 2020	EX-10.5	SUBSCRIPTION AGREEMENT Exhibit #10.5 SUBSCRIPTION AGREEMENT TO: The Board of Directors BioForce Nanosciences Holdings, Inc. 2020 General Booth Blvd., Unit 230 Virginia Beach, VA 23454 Dear Director: The undersigned, Richard Kaiser, hereby subscribes to 500,000 shares of the $0.0001 par value Preferred Series ‘A’ stock (the "Shares") of BioForce Nanosciences Holdings, Inc. (BFNH) a corporation duly organized under the la
May 4, 2020	EX-10.2	Employment Agreement - Kaiser (1) Exhibit 10.2 Director/ Chief Financial Officer/ Secretary Compensation AGREEMENT This Director, Chief Financial Officer/ Secretary (DCFOS) Compensation Agreement (this “Agreement”) is made as of the 31st day of March 2020 by and among Bioforce Nanosciences Holdings, Inc. (BFNH) a Delaware Corporation, having its principal place of business at 2020 General Booth Blvd., Unit 230 Virginia Beach, VA 2
May 4, 2020	EX-10.3	RSDL ENTERPRISES CONSULTING AGREEMENT Exhibit 10.3 RSDL ENTERPRISES CONSULTING AGREEMENT BioForce NanoSciences Holdings, Inc. desires to have services provided by Aldo Dalla-Vecchia of RSDL Enterprises. Therefore, the parties agree as follows: 1. DESCRIPTION OF SERVICES. Beginning on March 16, 2020, Aldo Dalla-Vecchia will provide the following services (collectively, the "Services"): General Consulting for Management 2. PERFORMANCE O
April 1, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (C
March 9, 2020	10-K/A	BFNH / BioForce Nanosciences Holdings, Inc. 10-K/A - Annual Report - AMENDED YEAR- END REPORT- DEC.31, 2019 10-K/A 1 bfnh03092020form10kadec2019.htm AMENDED YEAR- END REPORT- DEC.31, 2019 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1 to Form 10-K) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN
March 4, 2020	10-K	BFNH / BioForce Nanosciences Holdings, Inc. 10-K - Annual Report - YEAR - END REPORT-DEC.31, 2019 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-510
December 31, 2019	LETTER	LETTER December 31, 2019 Richard Kaiser Acting Chief Financial Officer BioForce Nanosciences Holdings, Inc.
December 31, 2019	EX-3.1	Amended Articles of Incorporation (1) EX-3.1 2 ex31.htm ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I Name The name of the Company is BioForce NanoSciences Holdings, Inc. ARTICLE II Business The purpose and nature of the business, objectives, or purposes to be transacted, promoted, or carried on by the Company shall be
December 31, 2019	DEFR14C	BFNH / BioForce Nanosciences Holdings, Inc. DEFR14C - - REVISED DEFINITIVE INFORMATION STATEMENT DEFR14C 1 bfnh12302019defr14c.htm REVISED DEFINITIVE INFORMATION STATEMENT SCHEDULE 14 C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION (Revised No. 1) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [X] Definitive Information Statement (Revised No.1) [ ] C
December 31, 2019	DEFR14C	BFNH / BioForce Nanosciences Holdings, Inc. DEFR14C - - REVISED DEFINITIVE INFORMATION STATEMENT NO. 2 INCLUDES EXHIBITS DEFR14C 1 bfnh12312019defr14c2.htm REVISED DEFINITIVE INFORMATION STATEMENT NO. 2 INCLUDES EXHIBITS SCHEDULE 14 C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION (Revised No. 2) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [X] Definitive Information State
December 31, 2019	TEXT-EXTRACT	BFNH / BioForce Nanosciences Holdings, Inc. TEXT-EXTRACT - - December 31, 2019 Richard Kaiser Acting Chief Financial Officer BioForce Nanosciences Holdings, Inc.
December 31, 2019	EX-99.1	PLAN OF RECAPITALIZATION Converted by EDGARwiz Exhibit 99.1 PLAN OF RECAPITALIZATION On November 22, 2019 the Board of Directors of BioForce Nanosciences Holdings, Inc. (the “Company”) adopted a resolution declaring it to be in the best interest of the Company and its Shareholders to effectuate a 5-to-1 reverse split of the Company’s Common Stock. In furtherance of that Plan, the Board of Directors hereby submits to the S
December 31, 2019	DEF 14C	BFNH / BioForce Nanosciences Holdings, Inc. DEF 14C - - DEFINITIVE INFORMATION STATEMENT SCHEDULE 14 C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [X] Definitive Information Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) BIOFORCE NANOSCIENCES HOLDINGS, INC.
December 27, 2019	EX-3.1	AMENDED AND RESTATED ARTICLES OF INCORPORATION BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I Name The name of the Company is BioForce NanoSciences Holdings, Inc. ARTICLE II Business The purpose and nature of the business, objectives, or purposes to be transacted, promoted, or carried on by the Company shall be to engage in any lawful activity, to do all and everything necessary, su
December 27, 2019	EX-99.1	PLAN OF RECAPITALIZATION Converted by EDGARwiz Exhibit 99.1 PLAN OF RECAPITALIZATION On November 22, 2019 the Board of Directors of BioForce Nanosciences Holdings, Inc. (the “Company”) adopted a resolution declaring it to be in the best interest of the Company and its Shareholders to effectuate a 5-to-1 reverse split of the Company’s Common Stock. In furtherance of that Plan, the Board of Directors hereby submits to the S
December 27, 2019	PRER14C	BFNH / BioForce Nanosciences Holdings, Inc. PRER14C - - REVISED PRELIMINARY INFO. STATEMENT SCHEDULE 14 C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION (Revised No.
December 27, 2019	CORRESP	BFNH / BioForce Nanosciences Holdings, Inc. CORRESP - - JONES & HALEY, P.C. ATTORNEYS AT LAW 750 HAMMOND DRIVE, SUITE 100, BUILDING 12 ATLANTA, GEORGIA 30328 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 December 27, 2019 United States Securities and Exchange Commission Division of Corporate Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Chris Edwards Re: BioForce
December 23, 2019	TEXT-EXTRACT	BFNH / BioForce Nanosciences Holdings, Inc. TEXT-EXTRACT - - December 20, 2019 Richard Kaiser Acting Chief Financial Officer BioForce Nanosciences Holdings, Inc.
December 23, 2019	LETTER	LETTER December 20, 2019 Richard Kaiser Acting Chief Financial Officer BioForce Nanosciences Holdings, Inc.
December 13, 2019	EX-99.1	PLAN OF RECAPITALIZATION EX-99.1 3 ex991.htm PLAN OF RECAPITALIZATION Exhibit 99.1 PLAN OF RECAPITALIZATION On November 22, 2019 the Board of Directors of BioForce Nanosciences Holdings, Inc. (the “Company”) adopted a resolution declaring it to be in the best interest of the Company and its Shareholders to effectuate a 5-to-1 reverse split of the Company’s Common Stock. In furtherance of that Plan, the Board of Directors
December 13, 2019	PRE 14C	BFNH / BioForce Nanosciences Holdings, Inc. PRE 14C - - PRELIMINARY INFORMATION STATEMENT PRE 14C 1 bfnh12132019pre14c.htm PRELIMINARY INFORMATION STATEMENT SCHEDULE 14 C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Definitive Information Statement [ ] Confidential, For Use of the Commission
December 13, 2019	EX-3.1	AMENDED AND RESTATED ARTICLES OF INCORPORATION BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I Name The name of the Company is BioForce NanoSciences Holdings, Inc. ARTICLE II Business The purpose and nature of the business, objectives, or purposes to be transacted, promoted, or carried on by the Company shall be to engage in any lawful activity, to do all and everything necessary, su
November 5, 2019	10-Q	BFNH / BioForce Nanosciences Holdings, Inc. 10-Q - Quarterly Report - QTR. ENDING SEPT. 30, 2019 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as spec
July 22, 2019	10-Q	BFNH / BioForce Nanosciences Holdings, Inc. 10-Q - Quarterly Report - QTR. ENDING JUNE 30, 2019 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified
April 30, 2019	10-Q	BFNH / BioForce Nanosciences Holdings, Inc. 10-Q Quarterly Report QTR. MARCH 31, 2019 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie
March 29, 2019	10-K	BFNH / BioForce Nanosciences Holdings, Inc. YEAR END REPORT- DECEMBER 31, 2018 (Annual Report) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-510
October 24, 2018	10-Q	BFNH / BioForce Nanosciences Holdings, Inc. QTR. REPORT-SEPT. 30, 2018 (Quarterly Report) 10-Q 1 bfnh10182018form10qsept.htm QTR. REPORT-SEPT. 30, 2018 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE
August 1, 2018	LETTER	LETTER Mail Stop 3030 August 1, 2018 Via E-mail Merle Ferguson President BioForce Nanosciences Holdings, Inc.
July 27, 2018	10-12G/A	BFNH / BioForce Nanosciences Holdings, Inc. AMENDED REGISTRATION STATEMENT U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 6 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Numb
July 24, 2018	10-Q	BFNH / BioForce Nanosciences Holdings, Inc. QTR. REPORT_JUNE 30, 2018 (Quarterly Report) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2018 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified
June 28, 2018	10-12G/A	BFNH / BioForce Nanosciences Holdings, Inc. AMENDED REGISTRATION STATEMENT U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 5 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Numb
June 28, 2018	CORRESP	BFNH / BioForce Nanosciences Holdings, Inc. CORRESP JONES & HALEY, P.C. ATTORNEYS AT LAW 750 HAMMOND DRIVE, SUITE 100, BUILDING 12 ATLANTA, GEORGIA 30328 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 June 28, 2018 Russell Mancuso, Branch Chief Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Tom Jones Re: BioFo
June 28, 2018	CORRESP	BFNH / BioForce Nanosciences Holdings, Inc. CORRESP U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 4 5 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Nu
June 19, 2018	LETTER	LETTER Mail Stop 3030 June 18, 2018 Via E-mail Merle Ferguson President BioForce Nanosciences Holdings, Inc.
May 25, 2018	10-12G/A	BFNH / BioForce Nanosciences Holdings, Inc. AMENDED REGISTRATION STATEMENT U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 4 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Numb
May 25, 2018	CORRESP	BFNH / BioForce Nanosciences Holdings, Inc. CORRESP JONES & HALEY, P.C. ATTORNEYS AT LAW 750 HAMMOND DRIVE, SUITE 100, BUILDING 12 ATLANTA, GEORGIA 30328 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 May 25, 2018 Russell Mancuso, Branch Chief Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Tom Jones Re: BioFor
May 25, 2018	CORRESP	BFNH / BioForce Nanosciences Holdings, Inc. CORRESP CORRESP 2 filename2.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 3 4 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporat
May 16, 2018	LETTER	LETTER Mail Stop 3030 May 15, 2018 Via E-mail Merle Ferguson President BioForce Nanosciences Holdings, Inc.
May 11, 2018	10-Q	BFNH / BioForce Nanosciences Holdings, Inc. QTR. REPORT- MARCH 31, 2018 (Quarterly Report) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2018 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie
April 25, 2018	10-12G/A	April, 25, 2018 04/25/2018 updated U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 3 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (C
April 25, 2018	EX-10.3	CONTRACT Converted by EDGARwiz Exhibit 10.3 CONTRACT Richard Kaiser agrees to provide Director and Corporate Officer services for BioForce Nanosciences Holdings, Inc. yearly, at no cost to the Company, and he continues to provide necessary office space and executive services in aforementioned space at no cost to Company. /s/ Richard Kaiser Director/Acting CFO/Secretary /s/ Merle Ferguson President/CEO/Chai
April 25, 2018	CORRESP	BFNH / BioForce Nanosciences Holdings, Inc. CORRESP JONES & HALEY, P.C. ATTORNEYS AT LAW SOUTH TERRACES, SUITE 170 115 PERIMETER CENTER PLACE ATLANTA, GEORGIA 30346-1238 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 April 25, 2018 Russell Mancuso, Branch Chief Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: To
April 25, 2018	CORRESP	BFNH / BioForce Nanosciences Holdings, Inc. CORRESP U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 2 3 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Nu
April 13, 2018	10-K	BFNH / BioForce Nanosciences Holdings, Inc. YEAR END REPORT- DECEMBER 31, 2017 (Annual Report) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-510
March 29, 2018	NT 10-K	BFNH / BioForce Nanosciences Holdings, Inc. NOTIFICATION OF LATE FILING (Check One): x Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 15, 2018	LETTER	LETTER Mail Stop 3030 March 14, 2018 Via E-mail Merle Ferguson President BioForce Nanosciences Holdings, Inc.
February 28, 2018	10-12G/A	BFNH / BioForce Nanosciences Holdings, Inc. AMENDED REGISTRATION STATEMENT U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 2 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Numb
February 28, 2018	CORRESP	BFNH / BioForce Nanosciences Holdings, Inc. CORRESP U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 1 2 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Nu
February 28, 2018	CORRESP	BFNH / BioForce Nanosciences Holdings, Inc. CORRESP JONES & HALEY, P.C. ATTORNEYS AT LAW SOUTH TERRACES, SUITE 170 115 PERIMETER CENTER PLACE ATLANTA, GEORGIA 30346-1238 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 February 28, 2018 Russell Mancuso, Branch Chief Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn:
February 13, 2018	LETTER	LETTER Mail Stop 3030 February 13, 2018 Via E-mail Merle Ferguson President BioForce Nanosciences Holdings, Inc.
January 26, 2018	CORRESP	BFNH / BioForce Nanosciences Holdings, Inc. CORRESP JONES & HALEY, P.C. ATTORNEYS AT LAW SOUTH TERRACES, SUITE 170 115 PERIMETER CENTER PLACE ATLANTA, GEORGIA 30346-1238 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 January 26, 2018 Russell Mancuso, Branch Chief Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn:
January 26, 2018	EX-10.2	Chairman Director EX-10.2 3 ex1002.htm MATERIAL CONTRACT Exhibit 10.2 Chairman Director Compensation AGREEMENT This Director Compensation Agreement (this “Agreement”) is made as of the 1st day of July, 2013 by and among BioForce Nanosciences Holdings, Inc. (BFNH), a Nevada Corporation, having its principal place of business at 2232 Virginia Beach Blvd, Virginia Beach, VA 23454 (“Company”), and Merle Ferguson, Chair
January 26, 2018	CORRESP	BFNH / BioForce Nanosciences Holdings, Inc. CORRESP U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identificatio
January 26, 2018	EX-10.1	Supplier Agreement (Previously filed as Exhibit 10.1 on Form 10/A)(1) Exhibit 10.1 Supplier Agreement This Supplier Agreement (this "Agreement") is made effective as of February 5th, 2015, between Body Align, LLC, of 2296 Chamberino Dr, Virginia Beach, Virginia 23456 ("Supplier"), and BioForce Nanosciences Holdings, Inc. (a Nevada Corporation) with its office at 3419 Virginia Beach, Suite 252, Virginia Beach, Virginia 23452("Customer"). This agreement will remain in
January 26, 2018	10-12G/A	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 1 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 1 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Numb
January 12, 2018	LETTER	LETTER Mail Stop 3030 January 11, 2018 Via E-mail Merle Ferguson Chief Executive Officer BioForce Nanosciences Holdings, Inc.
December 19, 2017	EX-3.1	Certificate of Incorporation (1) EX-3.1 2 ex31.htm ARTICLES OF INCORPORATIONS Exhibit- 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I Name The name of the Company is BioForce NanoSciences Holdings, Inc. ARTICLE II Business The purpose and nature of the business, objectives, or purposes to be transacted, promoted, or carried on by the Company shall be to engage in any lawful ac
December 19, 2017	EX-3.2	Bylaws (1) EX-3.2 3 ex32.htm BYLAWS Exhibit 3.2 BIOFORCE NANAOSCIENCES HOLDINGS, INC. AMENDED BY - LAWS ARTICLE I OFFICES Section 1. The principal office shall be in the City of Virginia Beach, Virginia. Section 2. The corporation may also have offices at such other places both within and without the State of Nevada as the board of directors may from time to time determine or the business of the corporation
December 19, 2017	10-12G	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identificatio
December 19, 2017	EX-4.1	EX-4.1 Exhibit 4.1
March 2, 2017	8-K	BioForce Nanosciences Holdings CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2017 BIOFORCE NANOSCIENCES HOLDINGS, INC (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 00
April 14, 2009	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-51074 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as
March 31, 2009	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 17, 2009	EX-99.1	EMPLOYEE COMPENSATION AGREEMENT EMPLOYEE COMPENSATION AGREEMENT THIS EMPLOYEE COMPENSATION AGREEMENT (the “Agreement”) is entered into this 11th day of March, 2009, by and between BioForce Nanosciences, Inc.
March 17, 2009	EX-99.2	PROMISSORY NOTE Attachment C1 PROMISSORY NOTE $92,253.82 Des Moines, Iowa February 25, 2009 FOR THE VALUE RECEIVED, BioForce Nanosciences, Inc., (the Borrower), located at 1615 Golden Aspen Drive, Suite 101, Ames, Iowa, 50010, promises to pay to the State of Iowa, Department of Economic Development (the "Department"), located at 200 East Grand Avenue, Des Moines, Iowa, 50309, the principal sum of ninety two thous
March 17, 2009	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2009 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (
February 6, 2009	EX-99.1	NOTICE OF DEFAULT OPPORTUNITY TO CURE NOTICE OF DEFAULT AND OPPORTUNITY TO CURE January 26, 2009 Greg Brown BioForce Nanosciences, Inc.
February 6, 2009	8-K	Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2009 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation)
January 15, 2009	EX-99.1	EX-99.1
January 15, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2009 BioForce Nanosci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2009 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation)
November 20, 2008	EX-10.1	CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT EX-10.1 4 ex101.htm MATERIAL CONTRACT CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT Dated as of November 17, 2008 among BIOFORCE NANOSCIENCES HOLDINGS, INC. and THE PURCHASERS LISTED ON EXHIBIT A CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT This CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT (the “Agreement”) is dated as of November 17
November 20, 2008	EX-4.2	WARRANT TO PURCHASE SHARES OF COMMON STOCK BIOFORCE NANOSCIENCES HOLDINGS, INC. Expires November 17, 2013 Date of Issuance: November 17, 2008 Number of Shares: 62,5000 Converted by EDGARwiz Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION. THE COMPANY MAY REFUSE TO AUTHORIZ
November 20, 2008	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2008 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation
November 20, 2008	EX-4.1	BIOFORCE NANOSCIENCES HOLDINGS, INC. CONVERTIBLE SECURED PROMISSORY NOTE EXHIBIT 4.1 THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION. THE COMPANY MAY REFUSE TO AUTHORIZE ANY TRANSFER OF THE S
November 14, 2008	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIENCES HOLDI
November 12, 2008	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 bfnh1111088k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2008 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State o
November 12, 2008	EX-4.2	Amendment Number 1 Employment Agreement Exhibit 4.2 Amendment Number 1 to Employment Agreement This Amendment Number 1 (the ?Amendment?) dated November 10, 2008, amends the Employment Agreement (the ?Agreement?) between BioForce Nanosciences Holdings, Inc. (the ?Company?) and Gregory D. Brown (the ?Employee?) In consideration of the mutual agreements set forth below and other good and valuable consideration, the receipt and adequacy of
November 12, 2008	EX-4.1	Amendment Number 3 Employment Agreement Exhibit 4.1 Amendment Number 3 to Employment Agreement This Amendment Number 3 (the ?Amendment?) dated November 6, 2008, amends the Employment Agreement (the ?Agreement?) between BioForce Nanosciences Holdings, Inc. (the ?Company?) and Kerry Frey (the ?Employee?) In consideration of the mutual agreements set forth below and other good and valuable consideration, the receipt and adequacy of which a
September 19, 2008	424B3	PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-146427 PROSPECTUS BIOFORCE NANOSCIENCES HOLDINGS, INC. 6,314,000 Shares of Common Stock This prospectus relates to the sale of up to an aggregate of 6,314,000 shares of our Common Stock which may be offered by the selling stockholders identified in this prospectus (the "selling stockholders") for their own account. Of such shares, 1,060,895shar
September 9, 2008	POS AM	POST EFFECTIVE AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - POST EFFECTIVE AMENDMENT NO. 2 TO FORM SB-2 ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITES ACT OF 1933 - BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in Its Charter) Nevada 3826 74-3078125 - - - (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organ
September 9, 2008	EX-10.43	EX-10.43 Ex. 10.43 Agreement Regarding SPT Grant This Agreement Regarding SPT Grant (the "Agreement") is made effective as of August 27, 2008 by and between Aspera Corp. ("Aspera") and BioForce Nanosciences, Inc. ("BioForce"). Whereas, Aspera and BioForce are both parties to a Shareholder Agreement relating to Aspera Corp. dated August 11, 2008 (the "Shareholder Agreement"), pursuant to which, among other
August 29, 2008	LETTER	LETTER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE Mail Stop 6010 August 29, 2008 VIA U.S. MAIL Gregory D. Brown Chief Financial Officer BioForce Nanosciences Holdings, Inc. 1615 Golden Aspen Drive Suite 101 Ames, Iowa 50010 RE: BioForce Nanosciences Holdings, Inc. Form 10-KSB for the fiscal year ended December 31, 2007 File No. 000-51074 Dear M
August 29, 2008	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1 to Form 10-Q) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1 to Form 10-Q) (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074
August 28, 2008	10QSB/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A (Amendment No. 1 to Form 10-QSB) BFNH 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A (Amendment No. 1 to Form 10-QSB) (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Num
August 27, 2008	10KSB/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB/A (Amendment No. 1 to Form 10-KSB) (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
August 26, 2008	CORRESP	- -1- August 26, 2008 Mr. Gary Todd United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Dear Mr. Todd: I am responding to your letter, dated July 22, 2008, with comments on our Form 10-KSB for the year ended December 31, 2007, and Form 10-QSB for the quarter ended March 31, 2008. Following are our responses to your comments. Form 10-KSB 1. Please see the enclosed m
August 14, 2008	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q BFNH 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIENCES H
August 13, 2008	EX-10.2	SHAREHOLDER AGREEMENT Relating to ASPERA CORP. (a Delaware corporation) Exhibit 10.2 SHAREHOLDER AGREEMENT Relating to ASPERA CORP. (a Delaware corporation) This Shareholder Agreement (Agreement) is entered into by and among the named Shareholders set forth on Exhibit A, attached hereto and made a part hereof, BioForce Nanosciences, Inc. (BioForce), and Aspera Corp. (Aspera), effective the 11th day of August, 2008 (Effective Date) with respect to the transfer of certa
August 13, 2008	EX-10.1	License Agreement Exhibit 10.1 License Agreement This License Agreement ("Agreement") is entered into as of the 11th day of August, 2008 by and between BioForce Nanosciences, Inc. ("BIOFORCE"), a Delaware corporation with its principal place of business located at 1615 Golden Aspen Dr., Ste 101, Ames, IA 50010-8098 USA, and Aspera Corp. (?ASPERA?), a Delaware corporation with its principal place of business located
August 13, 2008	EX-99.1	BIOFORCE NANOSCIENCES ENTERS INTO LICENSING AGREEMENT WITH ASPERA CORP. Operating Costs to be Reduced by 20% Annually; BioForce Receives Equity Interest in Aspera; Potential for Licensing Income to BioForce Exhibit 99.1 BIOFORCE NANOSCIENCES ENTERS INTO LICENSING AGREEMENT WITH ASPERA CORP. Operating Costs to be Reduced by 20% Annually; BioForce Receives Equity Interest in Aspera; Potential for Licensing Income to BioForce AMES, IA, August 12, 2008 - BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH), a producer of integrated biological and mechanical systems for life science researchers at the micr
August 13, 2008	EX-10.3	EMPLOYMENT AGREEMENT Exhibit 10.3 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) effective as of September 1, 2008 between BioForce Nanosciences Holdings, Inc (the “Company”), a Nevada corporation, and Eric R. Henderson (the “Employee”), a resident of the State of Iowa. WHEREAS, the Company wishes to employ the Employee to render services for the Company on the terms and conditions set forth in this Agre
August 13, 2008	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2008 BioForce Nanoscie UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2008 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation)
July 24, 2008	EX-99.1	BIOFORCE NANOSCIENCES COMPLETES SECOND PHASE OF FINANCING EXHIBIT 99.1 BIOFORCE NANOSCIENCES COMPLETES SECOND PHASE OF FINANCING AMES, IA, July 23, 2008 - BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH), a producer of integrated biological and mechanical systems for life science researchers at the micro and nano scales, today announced the completion of a $300,000 convertible debt financing. This is the second phase of the Company’s 2008 financing st
July 24, 2008	EX-4.2	WARRANT TO PURCHASE SHARES OF COMMON STOCK BIOFORCE NANOSCIENCES HOLDINGS, INC. Expires July 21, 2013 EXHIBIT 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION. THE COMPANY MAY REFUSE TO AUTHORIZE ANY TRANSFER OF THE
July 24, 2008	EX-4.1	BIOFORCE NANOSCIENCES HOLDINGS, INC. CONVERTIBLE SECURED PROMISSORY NOTE EX-4.1 2 ex41.htm RIGHTS OF SECURITY HOLDER EXHIBIT 4.1 THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION. THE COMPANY M
July 24, 2008	EX-10.1	CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT EX-10.1 4 ex101.htm MATERIAL CONTRACT EXHIBIT 10.1 CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT Dated as of July 21, 2008 among BIOFORCE NANOSCIENCES HOLDINGS, INC. and THE PURCHASERS LISTED ON EXHIBIT A CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT This CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT (the “Agreement”) is dated as of Ju
July 24, 2008	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2008 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (C
July 23, 2008	SC 13D/A	SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 Amendment No. 2* BioForce Nanosciences Holdings, Inc. - - (Name of Issuer) Common Stock, $0.001 par value - - (Title of Class of Securities) 09064C107 - - (CUSIP Number) Olivier Lecler, Chief Executive Officer Societe Generale Asset Management Alternative Investments, S.
July 22, 2008	LETTER	LETTER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE Mail Stop 6010 July 22, 2008 VIA U.S. MAIL and FACSIMILE Gregory D. Brown Chief Financial Officer BioForce Nanosciences Holdings, Inc. 1615 Golden Aspen Drive Suite 101 Ames, Iowa 50010 RE: BioForce Nanosciences Holdings, Inc. Form 10-KSB for the fiscal year ended December 31, 2007 Form 10-QSB f
July 11, 2008	POS AM	POS AM ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 11, 2008	EX-10.38	EX-10.38 AMENDMENT NUMBER 3 to the October 14, 2002 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment Number 3 to the October 14, 2002 Amended and Restated Registration Rights Agreement ( "Amendment Number 3"), made effective as of June 10, 2008, is by and between the Holders and BioForce Nanosciences Holdings, Inc.
June 20, 2008	SC 13D/A	SC 13D/A - OMB APPROVAL - OMB No. 3235-0145 - Exp. Feb 28, 2009 - Est avg burden - hrs/response. . . 15 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 Amendment No. 1* BioForce Nanosciences Holdings, Inc. - - (Name of Issuer) Common Stock, $0.001 par value - - (Title of Class of Securities) 09064C107 - - (CUSIP Number) Oli
June 20, 2008	SC 13D/A	SC 13D/A - - SEC 1746 (3-06) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
June 16, 2008	EX-99.1	EX-99.1 [LOGO] BioForce Nanosciences Holdings, Inc. BioForce Nanosciences Holdings, Inc. Investor Contact: Gregory D. Brown Porter, LeVay & Rose, Inc. Chief Financial Officer (212) 564-4700 515-233-8333 ext# 118 Marlon Nurse, VP - Investor Relations [email protected] [email protected] Jeffrey Myhre, VP - Editorial - - FOR IMMEDIATE RELEASE BIOFORCE NANOSCIENCES COMPLETES FINANCING Senior Manageme
June 16, 2008	EX-10.1	EX-10.1 CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT Dated as of June 10, 2008 among BIOFORCE NANOSCIENCES HOLDINGS, INC.
June 16, 2008	EX-4.2	EX-4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION.
June 16, 2008	8-K	8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2008 - BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction (Commission File N
June 16, 2008	EX-4.1	EX-4.1 THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION.
May 15, 2008	10QSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, I
May 15, 2008	EX-10.1	MASTER EQUIPMENT LEASE AGREEMENT LESSOR: RELATIONAL, LLC ADDRESS: 3701 Algonquin Road, Suite 600 Rolling Meadows, IL 60008 Tel: (847) 818-1700 LESSEE: BIOFORCE NANOSCIENCES, INC., a Delaware corporation DATE: March 28, 2008 ADDRESS: 1615 Golden Aspen EX-10.1 2 e603825ex10-1.htm MASTER EQUIPMENT LEASE AGREEMENT LESSOR: RELATIONAL, LLC ADDRESS: 3701 Algonquin Road, Suite 600 Rolling Meadows, IL 60008 Tel: (847) 818-1700 LESSEE: BIOFORCE NANOSCIENCES, INC., a Delaware corporation DATE: March 28, 2008 ADDRESS: 1615 Golden Aspen Drive, Suite 101 Ames, IA 50010 Lessee agrees to lease from Lessor the Equipment described in each related Schedule which
May 15, 2008	EX-10.2	AMENDMENT NUMBER 2 to the October 14, 2002 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT AMENDMENT NUMBER 2 to the October 14, 2002 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment Number 2 to the October 14, 2002 Amended and Restated Registration Rights Agreement ( “Amendment Number 2”), made effective as of May 5, 2008, is by and between the Holders and BioForce Nanosciences Holdings, Inc.
April 14, 2008	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 31, 2008	EX-4.2	USER SERVICE AGREEMENT USER SERVICE AGREEMENT This Agreement is made this 17th day of March, 2008 by and between CJM Financial, Inc.
March 31, 2008	EX-3.3	SILVER RIVER VENTURES, INC. * * * * * BY - LAWS * * * * * ARTICLE I SILVER RIVER VENTURES, INC. * * * * * BY - - LAWS * * * * * ARTICLE I OFFICES Section 1. The principal office shall be in the City of Clark Fork, Idaho. Section 2. The corporation may also have offices at such other places both within and without the State of Nevada as the board of directors may from time to time determine or the business of the corporation may require. ARTICLE II MEETINGS OF STOC
March 31, 2008	10KSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIENCES HOLDI
March 31, 2008	EX-4.1	ATTACHMENT B1 PROMISSORY NOTE BioForce Nanosciences ATTACHMENT B1 PROMISSORY NOTE BioForce Nanosciences IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT PIAP PROGRAM PROMISSORY NOTE Loan Number: 03-PIAP-04 Des Moines, Iowa $69,999 November 5, 2007 FOR VALUE RECEIVED, the undersigned (hereafter called the ?Maker?) promises to pay to the order of the State of Iowa, Department of Economic Development (hereafter called the ?Payee?) at its office at 200 East Gra
March 31, 2008	EX-10.9	AMENDMENT NUMBER 2 EMPLOYMENT AGREEMENT AMENDMENT NUMBER 2 to EMPLOYMENT AGREEMENT This AMENDMENT NUMBER 2 (“Amendment”) dated January 21, 2008 amends the Employment Agreement (“Agreement”) between BioForce Nanosciences Holdings, Inc.
March 31, 2008	EX-10.12	AMENDMENT NUMBER 2 EMPLOYMENT AGREEMENT AMENDMENT NUMBER 2 to EMPLOYMENT AGREEMENT This AMENDMENT NUMBER 2 (?Amendment?) dated January 21, 2008 amends the Employment Agreement (?Agreement?) between BioForce Nanosciences Holdings, Inc.
February 4, 2008	EX-99.1	EX-99.1
February 4, 2008	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2008 - BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction (Commission Fil
January 25, 2008	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2008 - BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction (Commission Fil
January 25, 2008	EX-99.1	EX-99.1 [LETTERHEAD] BIOFORCE NANOSCIENCES HOLDINGS, INC. Gregory D. Brown, Chief Financial Officer 515-233-8333 ext# 118 [email protected] FOR IMMEDIATE RELEASE BIOFORCE NANOSCIENCES' REORGANIZES SENIOR MANAGEMENT TEAM TO REFLECT TRANSITION TO COMMERCIAL ENTERPRISE Henderson to Focus on Scientific Side of Business Frey Brings 30 Years' Management and Operations Experience to CEO Job AMES, IA, Janua
November 21, 2007	EX-99.2	EX-99.2 BioForce Nanosciences Receives $500,000 from Investor Warrant Exercise AMES, Iowa, Nov.
November 21, 2007	8-K	8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2007 - BioForce Nanosciences Holdings, Inc. - (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 - - - - (State or other jurisdiction (Com
November 21, 2007	EX-99.1	EX-99.1 BioForce Nanosciences Reports Third Quarter 2007 Financial Results AMES, Iowa, Nov.
November 14, 2007	EX-10.2	EX-10.2
November 14, 2007	EX-10.1	EX-10.1
November 14, 2007	EX-10.3	AMENDMENT PROGRAM: PIAP CONTRACT NUMBER: 03-PIAP-04 AMENDMENT NUMBER: 1 EFFECTIVE DATE: October 30, 2007 EX-10.3 8 e602834ex10-3.htm Page of 1 Amendment No. 1 Contract No. 03-PIAP-04 AMENDMENT PROGRAM: PIAP CONTRACT NUMBER: 03-PIAP-04 AMENDMENT NUMBER: 1 EFFECTIVE DATE: October 30, 2007 THIS AMENDMENT is made by and between the IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT, (hereafter "Department"), 200 East Grand Avenue, Des Moines, Iowa 50309, an agency of the State of Iowa and BioForce Nanosciences, Inc
November 14, 2007	10QSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIEN
October 15, 2007	424B3	FORM 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-146427 PROSPECTUS BIOFORCE NANOSCIENCES HOLDINGS, INC. 6,314,000 Shares of Common Stock This prospectus relates to the sale of up to an aggregate of 6,314,000 shares of our Common Stock which may be offered by the selling stockholders identified in this prospectus (the "selling stockholders") for their own account. Of such shares, no shares wer
October 12, 2007	SB-2/A	SB-2/A As filed with the Securities and Exchange Commission on October 12, 2007 Registration No.
October 1, 2007	EX-99.1	EX-99.1 BioForce Nanosciences Holdings, Inc. Announces the Appointment of Michael Dunham to its Board of Directors AMES, Iowa, - (PrimeNewswire) - October 1, 2007- BioForce Nanosciences Holdings, Inc.(OTC BB: BFNH), a company focused on the development and commercialization of nanotech tools and solutions for the life sciences, today announced the appointment of Michael Dunham to its Board of Directors. M
October 1, 2007	SB-2	FORM SB-2 As filed with the Securities and Exchange Commission on October 1, 2007 Registration No.
October 1, 2007	EX-10.34	EX-10.34 AMENDMENT NUMBER 1 to the October 14, 2002 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment Number 1 to the October 14, 2002 Amended and Restated Registration Rights Agreement (the "Agreement"), made effective as of September 29, 2007, is by and between the Holders and BioForce Nanosciences Holdings, Inc.
October 1, 2007	EX-10.35	EX-10.35 Mr. Mike Dunham c/o WorkWise, Inc. 12000 W. Park Place Milwaukee WI 53224-3026 USA August 21, 2007 Dear Mike, It is my pleasure to offer you a seat on the Board of Directors for BioForce Nanosciences Holdings, Inc. The Board meets four times per year, with at least one (preferably two) meetings being held in person. I believe we can accommodate your annual travel schedule and living arrangements b
October 1, 2007	EX-10.6	EX-10.6 Exhibit 10.6 AMENDMENT NUMBER 2 to COMMERCIAL LEASE This LEASE AMENDMENT NUMBER 2 ("Amendment") dated September 20, 2007, between Randall Corporation, as Landlord, and BioForce Nanosciences, Inc., as Tenant, amends the lease consisting of the Commercial Lease dated November 19, 2004, and Lease Amendment Number 1 dated January 2, 2007 (collectively, the "Lease"). 1. All terms of the Lease shall con
September 7, 2007	EX-4.5	EX-4.5 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION.
September 7, 2007	EX-3.1	EX-3.1 CERTIFICATE OF DESIGNATION OF THE RELATIVE RIGHTS AND PREFERENCES OF THE SERIES A CONVERTIBLE PREFERRED STOCK OF BIOFORCE NANOSCIENCES HOLDINGS, INC.
September 7, 2007	EX-10.1	EX-10.1 SERIES A CONVERTIBLE PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT Dated as of August 31, 2007 among BIOFORCE NANOSCIENCES HOLDINGS, INC.
September 7, 2007	EX-4.1	EX-4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION.
September 7, 2007	EX-99.1	EX-99.1 BIOFORCE NANOSCIENCES COMPLETES FINANCING AMES , Iowa-September 4, 2007 - BioForce Nanosciences Holdings, Inc.
September 7, 2007	EX-4.4	EX-4.4 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION.
September 7, 2007	EX-4.3	EX-4.3 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION.
September 7, 2007	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2007 - BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other (Commission File Number) (IRS
September 7, 2007	EX-10.3	EX-10.3 LOCK-UP AGREEMENT THIS AGREEMENT (this "Agreement") is dated as of August 31, 2007 by and among BioForce Nanosciences Holdings, Inc.
September 7, 2007	EX-4.2	EX-4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION.
September 7, 2007	EX-4.7	EX-4.7 THIS WARRANT AND THE SHARES OF PREFERRED STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION.
September 7, 2007	EX-4.6	EX-4.6 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION.
September 7, 2007	EX-10.2	EX-10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this "Agreement") is made and entered into as of August 31, 2007, by and among BioForce Nanosciences Holdings, Inc.
September 7, 2007	EX-10.4	EX-10.4 [LOGO] TRIPOINT GLOBAL EQUITIES, LLC MEMBER: NASD/SIPC July 12, 2007 CONFIDENTIAL BioForce Nanosciences Holdings, Inc.
August 14, 2007	EX-10.1	EX-10.1 BIOFORCE NANOSCIENCES HOLDINGS, INC. AMENDED AND RESTATED 2006 EQUITY INCENTIVE PLAN 1. ESTABLISHMENT AND PURPOSE. 1.1 Establishment. BioForce Nanosciences, Inc., a Delaware corporation ("BioForce") previously established the Amended and Restated BioForce Nanosciences, Inc. 2000 Stock Incentive Plan (the "2000 Plan"). In 2003, BioForce established the BioForce Nanosciences, Inc. 2003 Stock Option
August 14, 2007	EX-10.3	EX-10.3 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this "Agreement"), effective as of August 13, 2007, between BioForce Nanosciences Holdings, Inc (the "Company"), a Nevada corporation, and Gregory D.
August 14, 2007	EX-10.4	EX-10.4 AMENDMENT NUMBER 1 to EMPLOYMENT AGREEMENT This AMENDMENT NUMBER 1 ("Amendment") dated June 13, 2007 amends the Employment Agreement ("Agreement") between BioForce Nanosciences Holdings, Inc.
August 14, 2007	10QSB	10QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB \|X\| QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2007 \|\| TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. - (Exact name
August 14, 2007	EX-10.5	EX-10.5 EX-10.5 6 e602444ex10-5.txt AMENDED EMPLOYMENT AGREEMENT, KERRY M. FREY AMENDMENT NUMBER 1 to EMPLOYMENT AGREEMENT This AMENDMENT NUMBER 1 ("Amendment") dated June 13, 2007 amends the Employment Agreement ("Agreement") between BioForce Nanosciences Holdings, Inc. (the "Company") and Kerry M. Frey (the "Employee"). In consideration of the mutual agreements set forth below and other good and valuabl
August 14, 2007	EX-10.2	EX-10.2 THIS OPTION AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER STATE OR FEDERAL SECURITIES LAWS.
August 10, 2007	EX-99.1	EX-99.1 [LETTERHEAD OF BIOFORCE NANOSCIENCES] BIOFORCE NANOSCIENCES REPORTS SECOND QUARTER 2007 FINANCIAL RESULTS AMES, IA-BioForce Nanosciences Holdings, Inc.
August 10, 2007	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2007 - BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction (Commission File
June 27, 2007	EX-99.1	From: Debra Happe [[email protected]] EX-99.1 [e-mail] From: Debra Happe [[email protected]] Sent: Monday, June 18, 2007 2:06 PM To: Debra Happe Subject: RedChip Initiates Research On BioForce Nanosciences Holdings, Inc. RedChip Visibility, a division of RedChip Companies, Inc. announced on June 12th that it has initiated research on BioForce Nanosciences Holdings, Inc. (OTC BB:BFNH.OB - News) Nancy Hull, MBA, RedChip Research A
June 27, 2007	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 18, 2007 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction (Commission (I.R.S.
June 19, 2007	EX-99.1	BIOFORCE NANOSCIENCES ANNOUNCES EXECUTIVE APPOINTMENTS [BioForce Nanosciences letterhead] FOR RELEASE: June 15, 2007, 12:02 p.m. EDT Contact: Investor Relations RedChip Companies Inc. Robert Rehse 1-800-REDCHIP (733-2447) ext 111 Company Contact: Deb Happe, Director of Communications 515-233-8333, Ext. 123 [email protected] BIOFORCE NANOSCIENCES ANNOUNCES EXECUTIVE APPOINTMENTS AMES, IA?BioForce Nanosciences Holdings, Inc. (OTCBB: BFNH) announce
June 19, 2007	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 BioForce Nanosciences Holdings, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2007 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125
May 25, 2007	EX-99.1	EX-99.1
May 25, 2007	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2007 BIOFORCE NANOSCIENCES HOLDINGS, INC.
May 15, 2007	10QSB	FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) \|X\| QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2007 \|\| TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS
May 14, 2007	EX-99.1	EX-99.1 [LETTERHEAD OF BIOFORCE NANOSCIENCES] FOR RELEASE: May 14, 2007, 1:30p.m. EDT Contact: Investor Relations: RedChip Companies Inc. Robert Rehse [email protected] 1-800-REDCHIP (733-2447) ext 111 www.redchip.com Company Contact: Deb Happe, Director of Communications 515-233-8333, Ext. 123 [email protected] BIOFORCE NANOSCIENCES REPORTS RECORD REVENUES, FIRST QUARTER 2007 FINANCIAL RESULTS AME
May 14, 2007	8-K	CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2007 - BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other (Commission File Number) (IRS Em
April 3, 2007	LETTER	LETTER MAIL STOP 3561 April 3, 2007 Mr. Eric Henderson, President Bioforce Nanosciences Holdings, Inc. 1615 Golden Aspen Drive, Suite 101 Ames, Iowa 50010 Re: Bioforce Nanosciences Holdings, Inc. Form 10-KSB for Fiscal Year Ended December 31, 2005 Filed April 17, 2006 File Number 000-51074 Dear Mr. Henderson: We have completed our review of your Form 10-KSB and related filings and have no further comment
April 2, 2007	EX-10.22	EX-10.22 ECONOMIC DEVELOPMENT COMMUNITY INVESTMENT FUND PROGRAM LOAN AGREEMENT (BIOFORCE NANOSCIENCES, INC.
April 2, 2007	EX-10.12	EX-10.12 BIOFORCE NANOSCIENCES, INC. 2003 STOCK OPTION PLAN This 2003 Stock Option Plan (this "Plan") of BioForce Nanosciences, Inc. (the "Company") is hereby established and provides for options (the "Option" or "Options") for the purchase of shares of the Company's common stock, with a par value of $0.01 per share ("Common Stock"). The Company intends that the Options will be either Incentive Stock Optio
April 2, 2007	EX-10.23	EX-10.23 Note and Warrant Purchase Agreement This NOTE AND WARRANT PURCHASE AGREEMENT, dated as of July 29, 2005 (this "Agreement"), is by and among BioForce Nanosciences, Inc.
April 2, 2007	EX-10.17	EX-10.17 NEITHER THIS SECURITY NOR ANY SECURITIES THAT MAY BE ISSUED UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), APPLICABLE STATE SECURITIES LAWS, OR APPLICABLE LAWS OF ANY FOREIGN JURISDICTION.
April 2, 2007	EX-10.7	EX-10.7 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this "Agreement") effective as of June 1, 2006 between BioForce Nanosciences Holdings, Inc (the "Company"), a Nevada corporation, and Kerry M.
April 2, 2007	EX-10.9	EX-10.9 Summary of Consulting Arrangement Between BioMedical Consulting LLC and BioForce Nanosciences, Inc.
April 2, 2007	EX-10.21	EX-10.21 CITY OF AMES ECONOMIC DEVELOPMENT REVOLVING LOAN FUND PROGRAM LOAN AGREEMENT (BIOFORCE NANOSCIENCES, INC.
April 2, 2007	10KSB	FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB (Mark One) \|X\| ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2006 \|\| TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIENCES HO
April 2, 2007	EX-10.4	EX-10.4 [LETTERHEAD OF GULFSTREAM CAPITAL GROUP, L.C.] December 12, 2006 Dr. Eric Henderson, CEO BioForce Nanosciences Holdings, Inc. 1615 Golden Aspen Drive, Suite 101 Ames, IA 50010 Dear Eric: The current relationship between our companies is reflected in the Consulting Agreement dated November 15, 2006. By this letter, we are mutually agreeing to extend the term of that agreement through December 31, 2
April 2, 2007	EX-10.13	EX-10.13 AMENDED AND RESTATED BIOFORCE NANOSCIENCES, INC. 2000 STOCK INCENTIVE PLAN Section 1. Purpose. The purpose of the Plan is to promote the interests of the Company and its shareholders by aiding the Company in attracting and retaining employees, officers, consultants, independent contractors and Non-Employee Directors capable of assuring the future success of the Company, to offer such persons incen
April 2, 2007	EX-10.20	EX-10.20 Contract Number 03-PIAP-04 BioForce Nanosciences Page 1 of 11 IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT PIAP LOAN AGREEMENT PIAP LOAN NUMBER: 03-PIAP-04 AWARD DATE: March 14, 2003 KIND OF AWARD: Loan and Forgivable Loan AWARD AMOUNT: $250,000 AGREEMENT EXPIRATION DATE: February 28,2006 THIS PHYSICAL INFRASTRUCTURE ASSISTANCE PROGRAM ("PIAP") AGREEMENT is made by and between the IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT, 200 East Grand Avenue, Des Moines, Iowa 50309 ("Department" or "IDED"), and BioForce Nanosciences, Iowa State University Research Parkm 2901 South Loup Drive, Suite 3400 Ames, IA 50010 ("Business").
April 2, 2007	EX-10.18	EX-10.18 THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933.
April 2, 2007	EX-10.1	EX-10.1 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of October 14, 2002, is by and among BioForce Nanosciences, Inc.
April 2, 2007	EX-10.15	EX-10.15 THIS OPTION AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER STATE OR FEDERAL SECURITIES LAWS.
April 2, 2007	EX-10.16	EX-10.16 BIOFORCE NANOSCIENCES, INC. INCENTIVE STOCK OPTION AGREEMENT THIS AGREEMENT is made this day of , 200, by and between BioForce Nanosciences, Inc., a Delaware corporation (the "Company"), and ("Employee"). WITNESSETH, THAT: WHEREAS, the Company wishes to grant this stock option to Employee pursuant to its 2000 Stock Incentive Plan (as it may be amended from time to time, the "Plan"). NOW, THEREFORE
April 2, 2007	EX-10.14	EX-10.14 THIS OPTION AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER STATE OR FEDERAL SECURITIES LAWS.
April 2, 2007	EX-10.19	EX-10.19 ================================================================================ COMMUNITY ECONOMIC BETTERMENT ACCOUNT (CEBA) "VENTURE PROJECT COMPONENT" ROYALTY AGREEMENT 02-VEN-03 BIOFORCE LABORATORY, Inc.
April 2, 2007	EX-10.2	EX-10.2 [LETTERHEAD OF BIOFORCE NANOSCIENCES] September 6, 2006 BioForce Nanosciences Holdings, Inc.
April 2, 2007	EX-3.1	EX-3.1 Office Use Only DEAN HELLER Articles of Incorporation Secretary of State (PURSUANT TO NRS 78) FILED # C31265-99 [Seal] 101 North Carson Street, Suite 3 DEC 10 1999 Carson City, nevada 89701-4755 (775) 684 5708 IN THE OFFICE OF /s/ Dean Heller DEAN HELLER SECRETARY OF STATE Important: Read attached instructions before completing form.
April 2, 2007	EX-10.3	EX-10.3 CONSULTING AGREEMENT THIS AGREEMENT, made as of this 15th day of November 2006, by and between Bioforce Nanosciences Holdings, Inc.
April 2, 2007	EX-10.10	EX-10.10 Summary of Compensation for Directors of BioForce Nanosciences Holdings, Inc. Non-employee directors receive no cash compensation for serving on our Board of Directors, and are granted non-qualified stock options upon joining the Board. The amounts and vesting schedules of these initial non-employee director stock option grants vary. Subsequent stock option grants to non-employee directors are at
April 2, 2007	EX-10.5	EX-10.5 [LOGO] RANDALL CORPORATION 420 South 17th Street Ames, Iowa 50010 Commercial Lease This Lease made on the date shown below by and between the Landlord, Randall Corporation, an Iowa Corporation, and the Tenant: BioForce Nanosciences, A Delaware Corporation If there is more than one Tenant, each shall be jointly and severally liable hereunder and all are collectively referred to as "Tenant".
March 23, 2007	SC 13D/A	AMENDMENT NO. 1 TO SCHEDULE 13D CUSIP No. 09064C107 - - SEC 1746 (3-06) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. - - UNITED STATES - SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL Washington, D.C. 20549 - OMB No. 3235-0145 SCHEDULE 13D/A - Exp. Feb 28, 2009 Under the Securities Exchange Act of 193
March 14, 2007	8-K/A	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 14, 2006 BIOFORCE NANOSCIENCES HOLDINGS, INC. - (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 - - - - (State or other jurisdiction (Com
March 14, 2007	CORRESP	CORRESP 3 Correspondence Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 SOUTH HIGHLAND DRIVE, SUITE 104 ATTORNEY AT LAW SANDY, UTAH 84093 TELEPHONE: (801) 733-0800 FAX: (801) 733-0808 E-MAIL: [email protected] March 14, 2007 Securities and Exchange Commission Attn: Tia Jenkins Senior Assistant Chief Accountant Office of Emerging Growth Companies 100 F Street, NE Washington, D.C. 2
March 9, 2007	EX-99.1	EX-99.1
March 9, 2007	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2007 BIOFORCE NANOSCIENCES HOLDINGS, INC.
January 29, 2007	LETTER	LETTER MAIL STOP 3561 January 26, 2007 Mr. Eric Henderson, President Bioforce Nanosciences Holdings, Inc. 1615 Golden Aspen Drive, Suite 101 Ames, Iowa 50010 Re: Bioforce Nanosciences Holdings, Inc. Form 10-QSB/A for the quarterly period ended March 31, 2006 File Number 000-51074 Dear Mr. Henderson: We have reviewed your amended filing and have the following comments. Where indicated, we think you should
January 16, 2007	EX-10.1	EX-10.1 December 27, 2006 Mr. Gregory D. Brown 9006 W. Meinecke Ave. Wauwatosa, WI 53226 Re: Offer of Employment Dear Greg, It is my pleasure to extend to you an offer of employment, contingent upon reference and background checks, with BioForce Nanosciences (the "Company"). We understand that your current employment requires you to provide 60 days notice of your intent to resign. Your employment start da
January 16, 2007	8-K	BIOF 8-K 011607 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2007 BioForce Nanosciences Holdings, Inc. - (Exact name of registrant as specified in its charter) Nevada 000-51074 76-3078125 - - - - (State or other jurisdiction (Commis
January 16, 2007	EX-99.1	EX-99.1 BIOFORCE 1415 Golden Aspen Drive PHN 1-515.233.8333 NANOSCIENCES Suite 101 FAX 1-515.233.8337 Ames, IA 50010-8090 USA FOR RELEASE: January 15, 2007, 9:30 a.m. EDT Contact: Deb Happe, Director of Communications 515-233-8333, Ext. 123 [email protected] BIOFORCE NANOSCIENCES HIRES CHIEF FINANCIAL OFFICER AMES, IA-BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH.OB) announced today the appoint
November 17, 2006	10QSB	BIOF 10QSB 093006 ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 17, 2006	10QSB/A	BIOF 10QSBA 093006 ================================================================================ SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

BFNH / BioForce Nanosciences Holdings, Inc. - Arquivamentos da SEC, Relatório Anual, Declaração de Procuração

Estatísticas Básicas

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?